mirvetuximab
immunogen
['mirvetuximab', 'gyn', 'ovarian']
 this is the first trial to show overall survival benefit in platinum resistant #ovariancancer. standard of care is clear! get the folr1 testing and identify the patients that will benefit from mirvetuximab
#asco23 #gyncsm 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc